Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)
20.60
+0.30 (1.48%)
Sep 15, 2026, 1:56 PM CST
TPEX:6704 Revenue
Gwo Xi Stem Cell Applied Technology Co. , had revenue of 65.33M TWD in the half year ending June 30, 2026, a decrease of -17.94%. This brings the company's revenue in the last twelve months to 157.86M, down -14.63% year-over-year. In the year 2025, Gwo Xi Stem Cell Applied Technology Co. , had annual revenue of 187.02M with 10.00% growth.
Revenue (ttm)
157.86M
Revenue Growth
-14.63%
P/S Ratio
12.34
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 187.02M | 17.00M | 10.00% |
| Dec 31, 2024 | 170.03M | 28.85M | 20.44% |
| Dec 31, 2023 | 141.18M | -39.49M | -21.86% |
| Dec 31, 2022 | 180.67M | -62.09M | -25.58% |
| Dec 31, 2021 | 242.75M | 54.21M | 28.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.05B |
| Synbio Tech | 1.01B |
| HeXun Biosciences | 308.21M |
| Sunny Pharmtech | 233.36M |
| G&E Herbal Biotechnology | 215.61M |
| TaiRx | 29.44M |
| Great Novel Therapeutics Biotech & Medicals | 6.21M |